The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-29

Study Completion Date

2021-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a Non-Interventional Study (NIS) with secondary data usage. It is designed as a multi-center retrospective cohort study in which the data of adult locally advanced HER2-positive breast cancer patients, who are treated with as neoadjuvant therapy, who underwent breast surgery in participating centers, were taken from hospital records.

The source population is academic or community oncology centers treating patients with breast cancer from Turkey.

The study population is planned to be the subgroup of breast cancer patients, who are treated with trastuzumab plus taxane with or without pertuzumab as neoadjuvant therapy, and underwent breast surgery at the participating centers.

The study is anticipated to include approximately 1500 patients from 20 sites.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT02131064

Breast Neoplasms

COMPLETED PHASE3

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients

NCT00429247

Breast Cancer

COMPLETED PHASE2

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

NCT06843681

Breast Carcinoma in Situ

ENROLLING_BY_INVITATION PHASE2

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

NCT03272477

Breast Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 2013, the Food and Drug Agency (FDA) granted accelerated approval to pertuzumab for use in the neoadjuvant setting with trastuzumab and chemotherapy for HER2+ locally advanced breast cancer (either greater than 2 cm in diameter or node positive), based on improvement in pCR in the NeoSphere (Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation) and TRYPHAENA (Trastuzumab plus Pertuzumab in Neoadjuvant HER2- positive Breast Cancer) studies. Full approval of pertuzumab in the early stage for patients at high risk of recurrence was recently received based on results of the adjuvant APHINITY study. NeoSphere study demonstrated a higher breast pCR rate with THP 17 (docetaxel, trastuzumab, pertuzumab) as compared to TH (breast pCR 45.8 versus 29%), and TRYPHAENA study also demonstrated high total pCR rates with FEC (5- fluorouracil, epirubicin, and cyclophosphamide)-THP (pCR 54.7%) and TCHP (docetaxel, carboplatin, HP, pCR 63.6%).

Pertuzumab is a humanized monoclonal antibody and is the first of a novel class of HER2-targeted agents known as HER2 dimerization inhibitors. This agent bind to a distinct epitope on the extracellular domain of the HER2 receptor (the domain II dimerization arm), blocking the interaction between HER2 and other HER family receptors. Potent inhibition of HER-mediated intracellular signaling results in cancer cell growth inhibition and death.

In Turkey, Pertuzumab has been authorized as neoadjuvant therapy for breast cancer patients since March 2019. Before this date pertuzumab was also available after patient- based approvals. Due to lack of local data regarding outcomes of pertuzumab in neoadjuvant therapy for breast cancer patients, this study will be the first in this area, in terms of national real world data.

This study is a Non-Interventional Study (NIS) with secondary data usage. It is designed as a multi-center retrospective cohort study in which the data of adult breast cancer patients, who are treated with as neoadjuvant therapy and underwent breast surgery in participating centers, were taken from hospital records.

NIS secondary data use based on electronic health records and paper files. Required key, primary and secondary variables will be ready including pCR data at the hospital records. If not, at the time of surgery there will be biopsy / imaging and other laboratory results, so primary or sub-investigator could also assess response and note as a source document.

All patients' data planned to be collected in line with this study protocol after the ethics approval of the study.

This retrospective design and secondary data use will help to reach endpoints in a short time with a 1500 target patient number.

This study is planned to be performed on nation-wide across Turkey from 20 oncology clinics.

The data will be collected into the database via an electronic case report form (e-CRF). Principal investigators at each participating site will be in charge of transferring patient data into the e-CRF. Data from the initial diagnosis of each patient until the last requested and available data in the patient charts at each participating site will be collected.

The primary variables for this study are as follows:

Demographics Clinical Information Diagnosis date Clinical Stage Pathological stage(TNM stage) Receptor status Histologic subtype Imaging details Neoadjuvant therapy Start date Stop date Response at the time of surgery Imaging after neoadjuvant treatment if available Recurrence if available Breast surgery Surgery type Operation date Imaging after operation Adjuvant therapy Start date Stop date Response Patients status (Ex, alive, last follow-up date,lost to follow-up)

Secondary Variables

The secondary variables for this study are as follows:

Adverse Events Incidence Therapy relationship Grade according to CTCAE Start/End date Outcomes : Hospitalization, intervention, ex, etc Recurrence date, death date if applicable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients aged 18 years old and over
* Patients diagnosed as histologically confirmed (IHC score of 3+ and/or positive by ISH) locally advanced HER2-positive breast cancer with breast surgery.
* Patients who received as neoadjuvant therapy.

Exclusion Criteria

* Patients transferred from an other hospital should not be included, however, patients' data transferred to an other hospital will be collected till transfer time

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No